Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.

Authors

Sean Khozin

Sean Khozin

U.S. Food and Drug Administration, Silver Spring, MD

Sean Khozin , Jizu Zhi , Monika Jun , Li Chen , Wendy S. Rubinstein , Mark S. Walker , George Anthony Komatsoulis , Jeremy Roberts , Ryan Fukushima , Denise Lau , Brigham Hyde , Edward Stepanski , Robert S. Miller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9110)

DOI

10.1200/JCO.2019.37.15_suppl.9110

Abstract #

9110

Poster Bd #

433

Abstract Disclosures